Table 1 Baseline Characteristics during Index hospitalization and follow-up
From: The use of enoxaparin as bridge to therapeutic INR after LVAD implantation
LMWH Index N = 43 | UFH Index N = 207 | P | LMWH follow-up N = 67 | UFH follow-up N = 177 | P | |
|---|---|---|---|---|---|---|
Demographics | ||||||
Age (SD) | 51.9 (15.3) | 56.1 (12.0) | 0.02 | 52.7 (13.8) | 56.6 (12.0) | 0.02 |
Males (%) | 29 (67.4) | 170 (82.1) | 0.03 | 58 (74.4) | 141 (82) | 0.17 |
Race (%) | 0.03 | 0.001 | ||||
Caucasian | 28 (65.1) | 167 (80.7) | 50 (64.1) | 145 (84.3) | ||
African American | 13 (30.2) | 39 (18.8) | 26 (33.3) | 26 (15.1) | ||
Others | 2 (4.7) | 1 (0.5) | 2 (2.6) | 1 (0.6) | ||
Type of LVAD (%) | 0.13 | 0.07 | ||||
HeartWare | 18 (41.9) | 84 (40.6) | 36 (46.2) | 66 (38.4) | ||
HeartMate II | 17 (39.5) | 52 (25.1) | 25 (32.1) | 44 (25.6) | ||
HeartMate III | 8 (18.6) | 71 (34.3) | 17 (21.8) | 62 (36.1) | ||
INTERMACS classification (%) | 0.55 | 0.18 | ||||
INTERMACS 1 | 7 (16.3) | 33 (15.9) | 11 (14.) | 29 (16.9) | ||
INTERMACS 2 | 13 (30.2) | 40 (19.3) | 24 (30.8) | 29 (16.9) | ||
INTERMACS 3 | 17 (39.5) | 110 (53.1) | 37 (47.4) | 90 (52.3) | ||
INTERMACS 4–7 | 6 (14.0) | 24 (12.0) | 6 (7.7) | 24 (14.0) | ||
Comorbidities (%) | ||||||
Cardiomyopathy | 0.32 | 0.38 | ||||
Ischemic | 17 (39.5) | 99 (47.8) | 33 (42.3) | 83 (48.3) | ||
Non-ischemic | 26 (60.5) | 108 (52.2) | 45 (57.7) | 89 (51.7) | ||
CAD | 20 (46.5) | 75 (36.2) | 0.21 | 34 (44.0) | 61 (35.5) | 0.22 |
Prior stroke | 7 (16.3) | 30 (15.0) | 0.76 | 14 (18.0) | 23 (13.34) | 0.35 |
CKD | 18 (42.0) | 33 (16.0) | < 0.01 | 30 (38.5) | 21 (12.2) | < 0.01 |
Atrial fibrillation | 0.005 | < 0.01 | ||||
Paroxysmal | 7 (16.3) | 85 (41.1) | 16 (20.5) | 76 (44.2) | ||
Permanent | 3 (6.9) | 5 (6.9) | 6 (7.7) | 2 (1.2) | ||
Hypertension | 29 (67.4) | 128 (61.8) | 0.49 | 55 (70.5) | 102 (59.3) | 0.09 |
Diabetes mellitus | 18 (41.9) | 102 (49.3) | 0.38 | 32 (41.0) | 88 (51.2) | 0.14 |
Obesity | 11 (25.6) | 80 (38.8) | 0.10 | 27 (34.6) | 64 (37.4) | 0.67 |
OSA | 9 (20.9) | 44 (21.4) | 0.95 | 23 (30.0) | 30 (17.5) | 0.03 |